stock price decline

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly misleading investors about Anaphylm drug approval prospects, citing undisclosed FDA deficiencies.

Law firm investigates $NNOX for potential securities violations following Q4 2025 net loss, $17.5M impairment charge, and 25% stock decline.

Law firm investigates Sportradar after Muddy Waters report alleges illegal gambling facilitation; stock falls 23% as securities violations reviewed.

Stellantis faces class action lawsuit alleging management concealed €22B restructuring needs. Stock plunged 23.69% after February 2026 disclosure of charges and business reset.

Federal securities lawsuit filed against Babcock & Wilcox for alleged misstatements regarding power generation contract. Stock fell 11.59% after conflict-of-interest report.

Globant faces securities fraud probe after 27.8% single-day stock plunge, weak Latin America revenue, and $47.6M restructuring charge.

Compass Therapeutics faces securities investigation after lead drug tovecimig fails overall survival endpoint in COMPANION-002 trial, triggering significant stock losses.

Law firm Johnson Fistel investigates POET Technologies after Marvell Semiconductor canceled all orders from subsidiary Celestial AI due to confidentiality breaches, triggering material stock decline.

Immutep shares plummet 82.6% after independent committee halts Phase III trial for lead candidate eftilagimod alfa due to futility.

Securities class action filed against $PINS over alleged false statements on ad revenues and tariff impacts. Stock plunged 16.8% in February 2026.

PennyMac Financial ($PFSI) stock collapsed 33.3% to $99.92 after weak Q4 results; securities investigation launched exploring class action lawsuit for alleged material misstatements.

Sportradar ($SRAD) stock crashes 22% after Muddy Waters alleges illegal gambling facilitation. Law firm launches securities fraud investigation.

ImmunityBio faces securities lawsuit over allegedly misleading Anktiva promotional materials. Stock fell 21% after FDA warning letter; investors can seek lead plaintiff status.

Hagens Berman sues $GEMI, alleging IPO documents concealed corporate pivot to prediction markets and executive departures. Stock plunged 75% from $28 IPO price.

Class action lawsuit filed against $ODD for allegedly concealing advertising partner algorithm changes that drove up customer acquisition costs, triggering 49% stock plunge.

Nektar Therapeutics faces securities fraud lawsuit over failed alopecia trial and alleged protocol disclosure violations. Stock fell 7.8% on December 16, 2025.

Gemini Space Station faces securities fraud lawsuit after stock plummeted from $28 IPO to $5.96, following revelations of false statements about crypto platform viability.

PennyMac ($PFSI) faces securities investigation after servicing income collapsed 76% sequentially, triggering 33% stock plunge on January 30, 2026.

Law firm Bragar Eagel & Squire investigates Sportradar after Muddy Waters report alleges illegal gambling facilitation. $SRAD stock declined following allegations.

Law firm Kirby McInerney investigates Elevance Health over CMS sanctions for Medicare Advantage noncompliance, triggering sharp stock decline.